Navigation Links
Emmaus CEO Yutaka Niihara, M.D., Issues Statement In Connection with Status of Company's Phase III FDA Sickle Cell Treatment Trials
Date:11/19/2012

TORRANCE, Calif., Nov. 19, 2012 /PRNewswire/ -- Following a meeting on November 5, 2012 with the U.S. Food & Drug Administration (FDA), Dr. Yutaka Niihara offered the following remarks:

"The FDA's review group unanimously recommended that we proceed to complete our Phase III trial without any modification to the protocol. The trial is directed to study L-glutamine as a treatment for sickle cell disease.

"We currently have 220 patients enrolled at 32 study sites throughout the United States.  We will continue enrollment until the end of 2012, with an objective to complete the trial in 2013.

"The FDA's recommendation on proceeding to complete the trial follows the preliminary review of a subset of data from the Phase III clinical trial that was completed by an independent third party in August of this year.  Emmaus received its initial authorization from the FDA to begin the Phase III trial in August 2009, with the first patient enrolled in mid-2010.

"We continue to believe that Emmaus is the only company with a Phase III trial underway for a new sickle cell treatment.  With research grants and through the support of friends, family and private investors over the past 20 years, we have progressed to the point where we are confident in our treatment and hopeful it will be in the hands of patients worldwide in the not too distant future."

About Emmaus Medical, Inc.

Founded in 2000, Emmaus Medical, Inc. is a specialty pharmaceutical company, and subsidiary of Emmaus Life Sciences, Inc., dedicated to the discovery, development and commercialization of innovative and cost-effective treatments and therapies for rare diseases. The company is completing its Phase III clinical trial for a treatment for sickle cell disease and has entered into a collaborative agreement for the research, development and commercialization of regenerative medicine technology products. For more information, please visit '/>"/>

SOURCE Emmaus Medical, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. European Commission Grants Orphan Medicinal Product Designation for Emmaus Medicals Sickle Cell Treatment
2. Emmaus Medical Marks Progression of Phase 3 Sickle Cell Disease Clinical Trial During Sickle Cell Awareness Month
3. Synthetic Biologics Appoints Carol Reed, M.D., as Senior Vice President of Clinical & Regulatory Affairs
4. Nile Therapeutics Appoints Darlene Horton, M.D., as Chief Medical Officer
5. Nile Therapeutics Promotes Darlene Horton, M.D., to Chief Executive Officer and Director
6. NIH Director Francis S. Collins, M.D., Ph.D. Selected as 2012 Pro Bono Humanum Honoree by Prix Galien USA
7. Sequenom Welcomes Myla Lai-Goldman, M.D., To Board Of Directors
8. Icahn Issues Statement Regarding Amylin Pharmaceuticals
9. Patient Advocate Foundation Announces New Co-Pay Relief (CPR) Offerings for Patients Facing Health Issues Due to Electrolyte Imbalance
10. U.S. Patent Office Issues Sixth Patent Covering Zero-Footprint Medical Image Viewers to Heart Imaging Technologies, LLC
11. Upcoming Presentations on Global Market Access Issues and Trends in Health Economics and Outcomes Research at ISPOR 2012 by Novel Health Strategies
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/29/2015)... 2015  PDL BioPharma, Inc. (NASDAQ: PDLI ) ... agreement with CareView Communications, Inc. (OTCQB: CRVW) whereby PDL ... secured debt financing. CareView is an information technology provider ... Under the credit agreement, PDL will provide ... in two tranches of $20 million, based upon the ...
(Date:6/29/2015)... , June 29, 2015  Allergan plc ... intends to release second quarter 2015 financial results ... open of the U.S. financial markets. The Company will ... a.m. Eastern Daylight Time on Thursday, August 6, ... to access the call is U.S./ Canada ...
(Date:6/29/2015)... TARRYTOWN, N.Y. , June 29, 2015 /PRNewswire/ ... today announced that the Proceedings of the ... a paper demonstrating that the Company,s proprietary VelociGene ... the rapid identification and preclinical validation of potential ... and treatment of Middle East Respiratory Syndrome (MERS). ...
Breaking Medicine Technology:PDL BioPharma Announces $40 Million Financing Transaction with CareView Communications 2PDL BioPharma Announces $40 Million Financing Transaction with CareView Communications 3PDL BioPharma Announces $40 Million Financing Transaction with CareView Communications 4Allergan to Host Second Quarter 2015 Earnings Conference Call and Webcast 2Allergan to Host Second Quarter 2015 Earnings Conference Call and Webcast 3Regeneron Rapid Response Platform for Emerging Infectious Diseases Described in Proceedings of the National Academy of Sciences Publication 2Regeneron Rapid Response Platform for Emerging Infectious Diseases Described in Proceedings of the National Academy of Sciences Publication 3Regeneron Rapid Response Platform for Emerging Infectious Diseases Described in Proceedings of the National Academy of Sciences Publication 4Regeneron Rapid Response Platform for Emerging Infectious Diseases Described in Proceedings of the National Academy of Sciences Publication 5
... DURHAM, N.C., May 1, 2012 Heart IT, ... approved zero footprint medical imaging workstation, WebPAX®, announced ... "zero-footprint" medical image viewing technologies. "Zero-footprint" technologies allow ... any computing platform with a standard Internet web ...
... 2012 Amarantus BioSciences, Inc. (OTCBB: AMBS), a ... the treatment of Parkinson,s disease and other nervous ... selected to present in the Emerging Companies Showcase ... Meeting on May 2nd, 2012 in New York ...
Cached Medicine Technology:U.S. Patent Office Issues Sixth Patent Covering 'Zero-Footprint' Medical Image Viewers to Heart Imaging Technologies, LLC 2Amarantus BioSciences to Present at the New York Biotechnology Association (NYBA) 21st Annual Meeting on May 2nd, 2012 2Amarantus BioSciences to Present at the New York Biotechnology Association (NYBA) 21st Annual Meeting on May 2nd, 2012 3
(Date:6/30/2015)... , ... June 30, 2015 , ... Isabel Healthcare announced ... to That Neighborhood Foundation for use in That Neighborhood Free Health Clinic. ... clinic with building and broadening differential diagnosis and expanding their perspective while working up ...
(Date:6/30/2015)... ... ... New Xarelto lawsuit claims proposed for consolidation in the ... to attorneys handling Xarelto lawsuits included in the MDL.* The forms, ... plaintiffs’ attorneys in filing new claims, according to court documents. Drafts of these ...
(Date:6/30/2015)... Petersburg, FL (PRWEB) , ... June 30, 2015 , ... Skin Brushing (also known as ... helpful to keep skin optimal and beautiful as it is more exposed to the elements. ... It can:, , Exfoliate the dead cells and toxins on skin's ...
(Date:6/30/2015)... , ... June 30, 2015 , ... ... June 24, 2015 amidst bright skies and inspirational words. , The independent, ... processional walk from the Glenholme building to the school’s Center for the Arts. ...
(Date:6/30/2015)... , ... June 30, 2015 , ... Intellitec Solutions has ... 2015 update to Dynamics CRM. With the enhanced changes and new procedures involved with ... The agenda will feature a look at the new user interface and what it ...
Breaking Medicine News(10 mins):Health News:Isabel Healthcare Donates Differential Diagnosis Decision Support Tool to That Neighborhood Foundation 2Health News:Isabel Healthcare Donates Differential Diagnosis Decision Support Tool to That Neighborhood Foundation 3Health News:Xarelto Lawsuit News: New Xarelto Lawsuit Filings to Be Expedited 2Health News:Xarelto Lawsuit News: New Xarelto Lawsuit Filings to Be Expedited 3Health News:Back in Stock: Keep Skin and Lymphatic System Healthy with Dry Skin Brushes from Sublime Beauty® 2Health News:The Glenholme School Graduates Its Class of 2015 2Health News:The Glenholme School Graduates Its Class of 2015 3Health News:The Glenholme School Graduates Its Class of 2015 4Health News:Intellitec Solutions to Host Microsoft CRM 2015 Update Webinar 2
... US researchers have discovered a non-invasive elastography technique that ... to radiation. ,The technique found by ... measuring muscle noise to reveal a patients condition. ... 16 sensors, each 1.5 centimetres apart, along the thigh ...
... Huxley has said that, "Although there was support for a ... of heart disease , the relationship is not as strong ... may have on heart disease are dwarfed by other risk ... ,Coronary heart disease is the leading cause ...
... who are hard of hearing. But the authorities have hardly ... problem has mysteriously persisted for decades in the Muslim-dominated Jhumarvad ... ,Shamshool Mia, a 62-year-old villager, said: "I am hard ... treatment failed to cure me. I will have to suffer ...
... public support for the fight against kidney diseases was kicked ... from the marathon, hosted by the New York Road Runners ... Arab Emirates (UAE), will go to the US National Kidney ... entrants from around the world, including 1000 women, 29 runners ...
... suspects in police custody is standard operating procedure for ... the idea that using a Taser could lead to ... the final results of a study conducted by emergency ... (UCSD) Medical Center showed no lasting effects of the ...
... Even before women with breast cancer undergo chemotherapy, ... activity levels, according to a new study ... in Omaha, Nebraska. ,Researchers say their ... following breast cancer surgery and before any further ...
Cached Medicine News:Health News:The Plight of Jharkhand's Mysterious deaf Village 2Health News:Healthy Humans Not Harmed By Taser 2Health News:Research Suggests Breast Cancer Fatigue Begins Before Chemo 2Health News:Research Suggests Breast Cancer Fatigue Begins Before Chemo 3
... gloves, Polymed has become even better. Polymed® TLC ... regular Polymed with the exciting addition of vitamin ... antioxidants, which are vital to healthy skin. Polymed ... to reduce the potential for latex sensitization. The ...
CYSTOSCOPY "T". DRAPE...
... for use in urology and gynecology. ... fluid strike-through, and help eliminate the need ... saving time and money (1071). 23 inch ... Drape, Clear plastic, Adhesive strip, Circle aperture, ...
... Both the Penilab IV and the Penilab V have ... Model 1060 is similar to the Model 1061 ... can one be added later. The Penilab V ... all of the accessories you'll need to get started. ...
Medicine Products: